HARMONi-6 Generates Enthusiasm as a Potential New Option for Squamous NSCLC

Join Dr. Benjamin Levy, along with thoracic medical oncologists Dr. Jarushka Naidoo and Dr. Bo Wang, as they dive into the exciting findings from the HARMONi-6 study presented at ASCO. This episode explores the implications of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, in combination with chemotherapy for patients with treatment-naïve squamous non-small cell lung cancer (NSCLC). In this discussion, the experts provide insights into the study's design, patient demographics, and key outcomes, including progression-free survival and overall survival rates. They also address the significance of the study's findings in the context of current treatment options and the challenges faced in treating advanced squamous cell lung cancer. Tune in to hear their thoughts on the potential impact of these results on clinical practice and the future of lung cancer treatment. Don't miss this informative episode that sheds light on a promising new therapy in a historically challenging patient population! Topics Covered: • Overview of the HARMONi-6 study • Efficacy and safety of ivonescimab plus chemotherapy • Patient demographics and baseline characteristics • Implications for clinical practice and future research Website: https://oncupdates.com/ Mail: [email protected] X/twitter: https://x.com/OncUpdates Subscribe for more updates on the latest in oncology research and treatments! #Ivonescimab, #SquamousNSCLC, #HARMONi6, #ASCO2026, #PD1VEGF